|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-9-15
|
|
pubmed:abstractText |
During therapy with tyrosine kinase inhibitors (TKIs), approximately 20% to 50% of patients with chronic myeloid leukemia (CML) develop grade >or=3 thrombocytopenia leading to treatment interruptions and dose reductions. Interleukin 11 (IL-11) reduces the incidence and the severity of thrombocytopenia in solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2008 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1338-43
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18629842-Adult,
pubmed-meshheading:18629842-Aged,
pubmed-meshheading:18629842-Drug Resistance, Neoplasm,
pubmed-meshheading:18629842-Humans,
pubmed-meshheading:18629842-Interleukin-11,
pubmed-meshheading:18629842-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18629842-Middle Aged,
pubmed-meshheading:18629842-Pilot Projects,
pubmed-meshheading:18629842-Piperazines,
pubmed-meshheading:18629842-Platelet Count,
pubmed-meshheading:18629842-Protein Kinase Inhibitors,
pubmed-meshheading:18629842-Protein-Tyrosine Kinases,
pubmed-meshheading:18629842-Pyrimidines,
pubmed-meshheading:18629842-Thrombocytopenia,
pubmed-meshheading:18629842-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article
|
